Ulipristal acetate for uterine fibroids: EMA recommends restricting use

CHMP endorsed PRAC’s assessment of risk of liver injury but considered benefits of ulipristal in controlling fibroids may outweigh risk. It therefore recommends ulipristal remains available to treat premenopausal women for whom surgical procedures are inappropriate/unsucessful.

Source:

European Medicines Agency